drugset / Trial / NCT00188812

Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease

NCT00188812

Non-randomizedSingle-groupOpen-labelTreatment

Summary

one year extension study following a previous double-blind study to evaluate safety of the drug

Timeline

Start
2004-05
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg
Subject Donepezil Small molecule 10 mg

Indications